Literature DB >> 2157058

Persistent nonproductive infection of Epstein-Barr virus-transformed human B lymphocytes by human immunodeficiency virus type 1.

K E Dahl1, T Burrage, F Jones, G Miller.   

Abstract

We have studied the interaction of different strains of human immunodeficiency virus type 1 (HIV-1) with an Epstein-Barr virus-transformed human B-lymphocyte line, X50-7. Previously we found that some HIV-1 strains replicated rapidly and were exclusively cytolytic; others induced persistent noncytopathic infection associated with continued shedding of extracellular virus (K. Dahl, K. Martin, and G. Miller, J. Virol. 61:1602-1608, 1987). We now describe a third form of cell-virus relationship in which infection by strain IIIB is maintained in a highly cell-associated state in a small subpopulation (less than 2%) of X50-7 cells. Neither viral subcomponents nor infectious virus was detectable in culture supernatants; however, the carrier lines were fusogenic and HIV-1 could be recovered following prolonged cocultivation with susceptible cells. In these chronic carrier cultures, virions were not seen budding at the cell surface, but a few were found within cytoplasmic vesicles. HIV-1 infection of first- and second-generation cell subclones of the carrier cell line rapidly evolved from a productive to a cell-associated state. There were low levels of HIV DNA, and RNA in the fusogenic secondary clones, but most clones lacked HIV-1 DNA, failed to express HIV-1 RNA, and exhibited no properties associated with HIV-1 infection. The experiments indicate that HIV-1 can be sequestered in human B lymphocytes. The cell cloning experiments introduce the possibility that the HIV-1 provirus may be lost from some lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157058      PMCID: PMC249315          DOI: 10.1128/JVI.64.4.1771-1783.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

2.  Trypsinized placental cell cultures for the propagation of viruses and as "feeder layers".

Authors:  E A Grogan; J F Enders; G Miller
Journal:  J Virol       Date:  1970-03       Impact factor: 5.103

3.  Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS.

Authors:  W A Andiman; R Eastman; K Martin; B Z Katz; A Rubinstein; J Pitt; S Pahwa; G Miller
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

4.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

5.  AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells.

Authors:  J A Levy; J Shimabukuro; T McHugh; C Casavant; D Stites; L Oshiro
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

6.  Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome.

Authors:  G M Shaw; B H Hahn; S K Arya; J E Groopman; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

7.  Demonstration of the absence of infectious Rous virus in rat tumour XC, whose structurally intact cells produce Rous sarcoma when transferred to chicks.

Authors:  J SVOBODA; P CHYLE; D SIMKOVIC; I HILGERT
Journal:  Folia Biol (Praha)       Date:  1963-04       Impact factor: 0.906

8.  Retrovirus and malignant lymphoma in homosexual men.

Authors:  A M Levine; P S Gill; P R Meyer; R L Burkes; R Ross; R D Dworsky; M Krailo; J W Parker; R J Lukes; S Rasheed
Journal:  JAMA       Date:  1985-10-11       Impact factor: 56.272

9.  Immunological and virological investigation in patients with lymphoadenopathy syndrome and in a population at risk for acquired immunodeficiency syndrome (AIDS), with particular focus on the detection of antibodies to human T-lymphotropic retroviruses (HTLV III).

Authors:  M C Sirianni; P Rossi; B Scarpati; G Ragona; R Seminara; G Bonomo; F Aiuti
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  6 in total

1.  Herpes simplex virus VP16 rescues viral mRNA from destruction by the virion host shutoff function.

Authors:  Q Lam; C A Smibert; K E Koop; C Lavery; J P Capone; S P Weinheimer; J R Smiley
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

2.  Human transformed trophoblast-derived cells lacking CD4 receptor exhibit restricted permissiveness for human immunodeficiency virus type 1.

Authors:  V Zachar; B Spire; I Hirsch; J C Chermann; P Ebbesen
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

Review 3.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

4.  Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency.

Authors:  D N Levy; Y Refaeli; D B Weiner
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

5.  Association between HIV and other DNA viruses in vitro.

Authors:  R Cisterna; C Campelo; T Gorriño; C Malavé; L Sarría; P Lardelli; A Fernandez de Aranguiz; L Madariaga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

6.  Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects.

Authors:  F di Marzo Veronese; D Arnott; V Barnaba; D J Loftus; K Sakaguchi; C B Thompson; S Salemi; C Mastroianni; A Sette; J Shabanowitz; D F Hunt; E Appella
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.